Table 3 |
|||||||||||
| Cardioversion Strategies by Country as Reported in the Site Questionnaires | |||||||||||
| Total | AUS | BR | FR | DEU | ITL | NL | POL | ESP | SWE | UK | |
| % (n/N) | % (n/N) | % (n/N) | % (n/N) | % (n/N) | % (n/N) | % (n/N) | % (n/N) | % (n/N) | % (n/N) | % (n/N) | |
| Frequency “wait-and-see” approach | |||||||||||
| never | 17.9 (31/173) | 12.5 (1/8) | 20.0 (2/10) | 12.0 (3/25) | 4.6 (1/22) | 0 | 0 | 20.0 (3/15) | 34.7 (17/49) | 0 | 28.6 (4/14) |
| sometimes | 69.4 (120/173) | 75.0 (6/8) | 50.0 (5/10) | 60.0 (15/25) | 90.9 (20/22) | 80.0 (8/10) | 100 (6/6) | 66.7 (10/15) | 59.2 (29/49) | 92.9 (13/14) | 57.1 (8/14) |
| frequent | 12.7 (22/173) | 12.5 (1/8) | 30.0 (3/10) | 28.0 (7/25) | 4.6 (1/22) | 20.0 (2/10) | 0 | 13.3 (2/15) | 6.1 (3/49) | 7.1 (1/14) | 14.3 (2/14) |
| Frequency PCV | |||||||||||
| never | 0.6 (1/173) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.1 (1/14) | 0 |
| sometimes | 37.6 (65/173) | 50.0 (4/8) | 20.0 (2/10) | 32.0 (8/25) | 68.2 (15/22) | 40.0 (4/10) | 50.0 (3/6) | 20.0 (3/15) | 14.3 (7/49) | 85.7 (12/14) | 50.0 (7/14) |
| frequent | 61.8 (107/173) | 50.0 (4/8) | 80.0 (8/10) | 68.0 (17/25) | 31.8 (7/22) | 60.0 (6/10) | 50.0 (3/6) | 80.0 (12/15) | 85.7 (42/49) | 7.1 (1/14) | 50.0 (7/14) |
| Frequency ECV | |||||||||||
| never | 0.6 (1/172) | 0 | 0 | 0 | 0 | 10.0 (1/10) | 0 | 0 | 0 | 0 | 0 |
| sometimes | 32.6 (56/172) | 25.0 (2/8) | 30.0 (3/10) | 16.7 (4/24) | 0 | 70.0 (7/10) | 0 | 6.7 (1/15) | 67.4 (33/49) | 14.3 (2/14) | 28.6 (4/14) |
| frequent | 66.9 (115/172) | 75.0 (6/8) | 70.0 (7/10) | 83.3 (20/24) | 100 (22/22) | 20.0 (2/10) | 100 (6/6) | 93.3 (14/15) | 32.6 (16/49) | 85.7 (12/14) | 71.4 (10/14) |
| Preferred drugs for PCV* | |||||||||||
| Amiodarone | 85.7 (150/175) | 100 (8/8) | 100 (10/10) | 81.5 (22/27) | 90.9 (20/22) | 60.0 (6/10) | 83.3 (5/6) | 93.3 (14/15) | 85.7 (42/49) | 64.3 (9/14) | 100 (14/14) |
| Beta-blocker | 23.4 (41/175) | 12.5 (1/8) | 40.0 (4/10) | 0 | 40.9 (9/22) | 10.0 (1/10) | 16.7 (1/6) | 53.3 (8/15) | 12.2 (6/49) | 28.6 (4/14) | 50.0 (7/14) |
| Dronedarone | 8.6 (15/175) | 0 | 0 | 0 | 45.5 (10/22) | 0 | 0 | 0 | 0 | 21.4 (3/14) | 14.3 (2/14) |
| Flecainide | 60.6 (106/175) | 75.0 (6/8) | 0 | 33.3 (9/27) | 81.8 (18/22) | 60.0 (6/10) | 100 (6/6) | 0 | 91.8 (45/49) | 35.7 (5/14) | 78.6 (11/14) |
| Propafenone | 26.9 (47/175) | 0 | 70.0 (7/10) | 3.7 (1/27) | 27.3 (6/22) | 80.0 (8/10) | 0 | 80.0 (12/15) | 20.4 (10/49) | 7.1 (1/14) | 14.3 (2/14) |
| Sotalol | 12.0 (21/175) | 75.0 (6/8) | 20.0 (2/10) | 0 | 0 | 10.0 (1/10) | 33.3 (2/6) | 26.7 (4/15) | 2.0 (1/49) | 7.1 (1/14) | 28.6 (4/14) |
| Verapamil | 6.3 (11/175) | 12.5 (1/8) | 10.0 (1/10) | 0 | 0 | 10.0 (1/10) | 0 | 13.3 (2/15) | 8.2 (4/49) | 0 | 14.3 (2/14) |
| Other† | 5.1 (9/175) | 0 | 0 | 0 | 0 | 10.0 (1/10) | 33.3 (2/6) | 0 | 6.1 (3/49) | 14.3 (2/14) | 7.1 (1/14) |
| Preferred type of ECV | |||||||||||
| Mono | 5.8 (10/173) | 0 | 10.0 (1/10) | 12.0 (3/25) | 4.6 (1/22) | 10.0 (1/10) | 0 | 0 | 6.1 (3/49) | 7.1 (1/14) | 0 |
| Biphasic | 94.2 (163/173) | 100 (8/8) | 90.0 (9/10) | 88.0 (22/25) | 95.5 (21/22) | 90.0 (9/10) | 100 (6/6) | 100 (15/15) | 93.9 (46/49) | 92.9 (13/14) | 100 (14/14) |
| Preferred heart rate target with rate control: | |||||||||||
| ≤ 80 beats per minute | 72.5 (124/171) | 100 (8/8) | 40.0 (4/10) | 87.5 (21/24) | 95.5 (21/22) | 90.0 (9/10) | 66.7 (4/6) | 86.7 (13/15) | 55.1 (27/49) | 57.1 (8/14) | 69.2 (9/13) |
| ≤ 110 beats per minute‡ | 25.1 (43/171) | 0 | 60.0 (6/10) | 12.5 (3/24) | 4.5 (1/22) | 10.0 (1//10) | 33.3 (2/6) | 13.3 (2/15) | 36.7 (18/49) | 42.9 (6/14) | 30.8 (4/13) |
| median, IQR | median, IQR | median, IQR | median, IQR | median, IQR | median, IQR | median, IQR | median, IQR | median, IQR | median, IQR | median, IQR | |
| n§ | n | n | n | n | n | n | n | n | n | n | |
| No. ECVs/year | 100 (50–200) | 105 (90–200.5) | 30 (9–70) | 120 (85–200) | 300 (150–500) | 85 (15–200) | 225 (115–300) | 70 (40–120) | 50 (24–126.5) | 225 (80–280) | 111(100–168) |
| n = 170 | n = 8 | n = 10 | n = 23 | n = 22 | n = 10 | n = 6 | n = 15 | n = 48 | n = 14 | n = 14 | |
|
No. PCVs/ year |
100 (37.5-200) | 102 (32.5-185) | 50 (20–80) | 150 (30–200) | 60 (25–100) | 175 (100–250) | 108 (50–200) | 150 (40–250) | 121 (98–300) | 15 (4–30) | 68 (30–140) |
| n = 168 | n = 8 | n = 9 | n = 22 | n = 21 | n = 10 | n = 6 | n = 15 | n = 48 | n = 14 | n = 14 | |
| Number of ablation procedures (among those performing ablations) | 156 (53–300) | 46 (35–179) | 64 (20–180) | 300 (112–450) | 300 (155–400) | 210 (120–480) | 440 (279–669) | 105 (53–171) | 125 (40–188) | 250 (120–856) | 35 (19–88) |
| n = 112 | n = 6 | n = 10 | n = 19 | n = 18 | n = 6 | n = 4 | n = 12 | n = 29 | n = 3 | n = 5 | |
PCV, pharmacologic cardioversion; ECV, electrical cardioversion.
*Preferred drugs for PCV- sites had the option to choose one or more of drug options given, in addition to other.
†Other does not include bepridil, cibenzoline, cordichin, moricizine, tocainide which were “0” for all.
‡ ≤ 110 beats per minute: bpm: > 80 and ≤ 110.
§n = number of sites.
Crijns et al. BMC Cardiovascular Disorders 2012 12:85 doi:10.1186/1471-2261-12-85
